Opinion|Videos|November 4, 2024
Prostate Cancer and Intimacy
Key Takeaways
- Advanced prostate cancer treatment can affect intimacy and QOL, necessitating open communication with healthcare providers.
- Patients should articulate their treatment goals and preferences to influence decision-making and treatment aggressiveness.
Panelists discuss how the diagnosis and treatment of advanced prostate cancer can significantly impact intimacy and relationships, emphasizing the importance of open communication about goals and preferences in treatment decisions, while also sharing strategies for self-advocacy and maintaining quality of life (QOL) throughout the treatment journey.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can the diagnosis and treatment of advanced prostate cancer affect intimacy for patients? What advice do you offer patients?
- How has your diagnosis and treatment impacted your intimate relationships, and what advice would you give to others?
TOPIC IV: Advocating for Yourself (~5 minutes)
- How important is it for patients to share their goals and preferences in treatment decisions? What role do their preferences play in your treatment decisions, including how aggressive to be?
- How did you speak up for yourself during your treatment journey? What strategies worked for you? What advice would you offer others?
- What should patients consider when talking to their doctors about the risks and benefits of treatments?
- What were your main concerns, and how did you talk about them with your doctor? Do you have any questions that someone going through a similar journey should ask their care team?
- How do QOL issues affect treatment decisions?
- How has your treatment impacted your daily life and overall QOL? Did you have any strategies to help maintain your QOL and continue to be able to do what was important to you?
Advertisement
Related to this article
Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
Advertisement
Advertisement